Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
T. T. Robinson, R. L. Bowman, S. Persaud, Y. Liu, Q. Gao, J. Zhang, X. Sun, L. A. Miles, S. F. Cai, A. Sciambi, A. Llanso, F. A. Christopher, A. D. Goldberg, A. Dogan, M. Roshal, , W. Xiao
The paper develops a single-cell MRD assay that detects residual leukemic clones with high sensitivity and reveals clonal architecture in AML.
bioRxiv · Sep 20, 2022 · PreprintPathology
B. T. Diamond, B. Ziccheddu, K. H. Maclachlan, J. Taylor, E. Boyle, J. Arrango Ossa, J. T. Jahn, M. Affer, T. M. Totiger, D. G. Coffey, J. Watts, S. X. Lu, N. Bolli, K. Bolton, J. H. Park, , F. Maura
The paper reconstructs the evolutionary history of therapy-related myeloid neoplasms using chemotherapy-associated mutational signatures and identifies distinct mutational patterns linked to different chemotherapies.
bioRxiv · Apr 26, 2022 · PreprintCancer Biology
F. MAURA, B. Ziccheddu, J. J. Xiang, B. Bhinder, F. Abascal, K. Maclachlan, K. W. Eng, M. Uppal, F. He, W. Zhang, Q. Gao, V. Yellapantula, S. Park, M. Oberley, E. Ruckdeschel, , L. Giulino-Roth
This study uses whole genome sequencing of Hodgkin and Reed Sternberg cells to reconstruct the temporal evolution of classic Hodgkin lymphoma, identifying key mutations and structural variants.
bioRxiv · Nov 5, 2021Cancer Biology
W. Xiao, A. Chan, M. R. Waarts, T. Mishra, Y. Liu, S. F. Cai, J. Yao, Q. Gao, R. L. Bowman, R. Koche, I. S. Csete, J. Baik, S. Yanis, C. Famulare, M. Patel, , R. Levine
This study identifies pDC-AML as a distinct AML subset with high RUNX1 mutations and pDC transcriptional features, suggesting CD123 targeting as a therapeutic strategy.
Blood · Mar 11, 2021Peer-reviewedPathology
J. J. Harding, M. A. Lowery, A. H. Shih, J. M. Schvartzman, S. Hou, C. Famulare, M. Patel, M. Roshal, R. K. G. Do, A. Zehir, D. You, S. D. Selcuklu, A. Viale, M. S. Tallman, D. M. Hyman, , A. M. Intlekofer
The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.
bioRxiv · Aug 1, 2018Cancer Biology